GSK-101468/228



A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.
ropinirole
101468/228
NCT00363727
Parkinson Disease
Phase 3
 
June 2014